Between the two groups, there were no significant differences in pre-mobilization WBC counts and serum LDH levels. However, the ratio of the LDH level immediately before apheresis to the lowest one ("LDH-ratio") were significantly lower in poor mobilizers than good mobilizers. Our ROC analysis showed that the cut-off value of "LDH-ratio" was 1.75. An elevation of serum LDH levels to reach "LDH-ratio">1.75 were found to be a useful predictive factor for successful CD34+ stem cell collection. The delay in reaching "LDHratio">1.75 may suggest that we should modify the mobilization regimen by, for instance, adding prelixafor.
1 Hematology/ Oncology, Palo Alto Medical Foundation, Mountain View, CA; 2 Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA Background: An HCT-CI score of 3 demonstrated significant differences in non-relapse mortality (NRM) and overall survival independent from Karnofsky Performance Status (KPS) in allogeneic HCT recipients. An HCT-CI score of 3 did not predict NRM and survival in multiple myeloma (MM), Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL), but did predict significant differences in the development of grade 3-5 toxicities in NHL patients. Purpose: Use of HCT-CI score to predict grade 3-5 toxicities within 90 days post-autologous HCT in elderly patients. Method: Retrospectively utilized an HCT-CI score of 3 to predict grade 3-5 toxicities in autologous HCT patients ! 65 years in a single HCT center in 2011. Outcome variables included pulmonary (pneumonitis or fibrosis), gastrointestinal (diarrhea, nausea or mucositis), neurologic (confusion), renal dysfunction (increased creatinine), hepatic dysfunction (increased ALT/ AST), cardiovascular (decreased ejection fraction, and atrial or ventricular arrythmias), fatigue and bone pain. Grading criteria were based on the National Cancer Institute Common Terminology Criteria Adverse Events version 4.0. Results: The sample consisted of 37 autologous HCT recipients a mean of 67.4 years (range of 65-71), including 19 males (51.4%) and 18 females (48.6%) with the following diagnoses MM (13), HL (1) NHL (21) and amyloidosis (2). At the time of transplant, 59.5% were not in complete remission. KPS score was ! 80% in all patients and ! 90% in 33 (89.2%). One patient expired 19 days post-HCT and two suffered a relapse 55 and 107 days post-HCT, respectively. Each of these three patients had HCT-CI scores !3. Utilizing HCT-CI criteria, 23 (62.1%) had decreased pulmonary function, 6 (16.2%) had decreased cardiovascular function, 3 (8.1%) had solid tumor history, and 3 (8.1%) had depression or anxiety.
Using an HCT-CI score of 3, 18 patients scoring ! 3 developed 44 grade 3-5 toxicities, while 19 patients with a score < 3 developed 20 grade 3-5 toxicities (p ¼ .002). ANCOVA multivariate analysis demonstrated that an HCT-CI score of 3 can predict the number of grade 3-5 toxicities (p ¼ .044) independently from age, gender, KPS, diagnoses, and pre-transplant disease status. Conclusion: This retrospective study utilizing an HCT-CI score of 3 predicted grade 3-5 toxicity in the first 90 days following HCT in elderly autologous HCT recipients independent of KPS, diagnoses, disease status, age, and gender. The predictive ability of the HCT-CI is superior to performance status. Adding HCT-CI to pre-HCT eligibility criteria for elderly patients should be considered. Use of the HCT-CI may also be utilized as part of pre-HCT counseling and education. Chemotherapy and G-CSF were used if therapy or cytoreduction was necessary and, per institutional guideline, cytokine only mobilization was G-CSF 10 ug/kg daily with apheresis starting on day 5, and plerixafor 0.24 mg/kg was added on day 4 if the peripheral blood CD34+ cells/ul was < 15. A total of 343 pts underwent 362 attempts at collection with 56 (15%) having type II DM. Failure to mobilize CD34 cells was defined as never reaching 10 or greater peripheral blood CD34+ cells/ul, or collecting less than 2 million CD34+ cells/kg. Both DM and non-DM pts required a median of 2 (range 1-4) days of apheresis for successful collection. The mean total CD34+ cells/kg x 10 6 collected (std dev) was 6.12 (2.66) in DM pts vs 6.8 (3.58) in non-DM pts (p¼0.05). When stratified by method of mobilization, the mean and median total CD34+ cells collected were less, and the mean days of apheresis were more in DM pts, but this did not reach statistical significance. Overall, 11/343 (3.2%) pts failed to mobilize adequate CD34+cells and did not proceed to autologous HSC transplant, with 4 of the 11 (36%) having DM. Engraftment and day 100 transplant outcomes were not different between pts with and without DM. In conclusion, pts with DM may mobilize less CD34+ cells, but this appears to be a small effect that is primarily overcome by current methods of mobilization, with the majority of patients still able to proceed to autologous HSC transplant. Larger studies 
